Trial Profile

A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 13 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bucindolol (Primary)
Indications Chronic heart failure
Focus Registrational; Therapeutic Use
Acronyms BEST

Most Recent Events

06 Mar 2019 According to an ARCA biopharma Inc media release, data from a retrospective analysis of prospectively designed DNA substudies from BEST and HF-ACTION were published in Circulation.
06 Mar 2019 Results presented in an ARCA biopharma Inc Media Release.
15 Nov 2017 Results assessing recovery of ventricular function in patients with chronic heart failure by taking patients data from BEST study, presented at the 90th Annual Scientific Sessions of the American Heart Association.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com